Abstract

Stem cell-derived islet organoids constitute a promising treatment of type 1 diabetes. A major hurdle in the field is the lack of appropriate in vivo method to determine graft outcome. Here, we investigate the feasibility of in vivo tracking of transplanted stem cell-derived islet organoids using magnetic particle imaging (MPI) in a mouse model. Human induced pluripotent stem cells-L1 were differentiated to islet organoids and labeled with superparamagnetic iron oxide nanoparticles. The phantoms comprising of different numbers of labeled islet organoids were imaged using an MPI system. Labeled islet organoids were transplanted into NOD/scid mice under the left kidney capsule and were then scanned using 3D MPI at 1, 7, and 28 days post transplantation. Quantitative assessment of the islet organoids was performed using the K-means++ algorithm analysis of 3D MPI. The left kidney was collected and processed for immunofluorescence staining of C-peptide and dextran. Islet organoids expressed islet cell markers including insulin and glucagon. Image analysis of labeled islet organoids phantoms revealed a direct linear correlation between the iron content and the number of islet organoids. The K-means++ algorithm showed that during the course of the study the signal from labeled islet organoids under the left kidney capsule decreased. Immunofluorescence staining of the kidney sections showed the presence of islet organoid grafts as confirmed by double staining for dextran and C-peptide. This study demonstrates that MPI with machine learning algorithm analysis can monitor islet organoids grafts labeled with super-paramagnetic iron oxide nanoparticles and provide quantitative information of their presence in vivo.

Highlights

  • Type 1 diabetes (T1D) is characterized by an absolute deficiency of insulin secretion with hyperglycemia as a consequence

  • All human induced pluripotent stem cells (hiPSCs) lines were validated for pluripotency and genomic integrity. hiPSC-L1 were cultured in Essential 8 Flex medium (Thermo Fisher Scientific, MA, United States) containing 1% penicillin/streptomycin (Gibco, Thermo Fisher Scientific, MA, United States) on six-well plates coated with growth factorreduced Matrigel (Corning, NY, United States) in an incubator at 37◦C, 5% CO2, until 60–80% confluency was reached, at which point cells were split into new wells using ReLeSR passaging reagent (STEMCELL Technologies, Vancouver, BC, Canada)

  • SPSS statistical software (IBM, Armonk, NY, United States) was used to calculate intraclass correlation coefficient (ICC), which provides a measure of the inter-rater reliability between the rater and algorithm

Read more

Summary

Introduction

Type 1 diabetes (T1D) is characterized by an absolute deficiency of insulin secretion with hyperglycemia as a consequence. In recent years advances in stem cell research, such as the derivation of human induced pluripotent stem cells (hiPSCs) and the emergence of organoid technologies, have enabled the creation of highly sophisticated human tissues and organ-like structures in vitro. These tissues could be used for isogenic or allogenic transplantation in the clinical setting to treat a diverse number of conditions, including T1D. In vitro created pancreatic islet organoids can be readily generated from hiPSCs matching the patient, providing an alternative similar to cadaveric donor islets that bypasses immune rejection concerns. A significant hurdle, is monitoring integration and survival of the pancreatic islet organoid after transplantation, and the lack of suitable noninvasive imaging techniques allowing us to determine the longerterm graft outcome (Rizzo et al, 2017; Wang and Aguirre, 2018)

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call